Regeneron and Sanofi Get Approval for Dupixent to Treat Moderate-to-Severe Bullous Pemphigoid in Japan
Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare, or MHLW, in Japan has approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid. The approval in Japan is based on data from the pivotal LIBERTY-BP-ADEPT Phase 2/3 trial, which evaluated Dupixent in adults with moderate-to-severe BP.
